MedRx Co., Ltd (TYO:4586)
Japan
· Delayed Price · Currency is JPY 99.00
-8.00 (-7.48%)
Mar 9, 2026, 3:30 PM JST
MedRx Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 3 | - | 7 | 9 | 8 | Upgrade
|
| Other Revenue | 125 | 257 | 22 | 50 | - | Upgrade
|
| Revenue | 128 | 257 | 29 | 59 | 8 | Upgrade
|
| Revenue Growth (YoY) | -50.20% | 786.21% | -50.85% | 637.50% | -93.04% | Upgrade
|
| Cost of Revenue | 2 | - | 3 | 3 | 2 | Upgrade
|
| Gross Profit | 126 | 257 | 26 | 56 | 6 | Upgrade
|
| Selling, General & Admin | 1,068 | 203 | 221 | 232 | 270 | Upgrade
|
| Research & Development | - | 846 | 737 | 921 | 794 | Upgrade
|
| Operating Expenses | 1,068 | 1,050 | 960 | 1,157 | 1,067 | Upgrade
|
| Operating Income | -942 | -793 | -934 | -1,101 | -1,061 | Upgrade
|
| Interest Expense | - | - | - | - | -1 | Upgrade
|
| Interest & Investment Income | 2 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -5 | -1 | 11 | -3 | 1 | Upgrade
|
| Other Non Operating Income (Expenses) | 8 | 40 | -7 | -8 | -12 | Upgrade
|
| EBT Excluding Unusual Items | -937 | -754 | -930 | -1,112 | -1,073 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -68 | - | - | - | Upgrade
|
| Other Unusual Items | 12 | 20 | - | 2 | 15 | Upgrade
|
| Pretax Income | -925 | -802 | -930 | -1,110 | -1,058 | Upgrade
|
| Income Tax Expense | 12 | 4 | 2 | 1 | 1 | Upgrade
|
| Net Income | -937 | -806 | -932 | -1,111 | -1,059 | Upgrade
|
| Net Income to Common | -937 | -806 | -932 | -1,111 | -1,059 | Upgrade
|
| Shares Outstanding (Basic) | 54 | 43 | 35 | 25 | 21 | Upgrade
|
| Shares Outstanding (Diluted) | 54 | 43 | 35 | 25 | 21 | Upgrade
|
| Shares Change (YoY) | 23.62% | 24.99% | 37.12% | 18.76% | 31.47% | Upgrade
|
| EPS (Basic) | -17.44 | -18.54 | -26.80 | -43.80 | -49.58 | Upgrade
|
| EPS (Diluted) | -17.44 | -18.54 | -26.80 | -43.80 | -49.58 | Upgrade
|
| Free Cash Flow | -970 | -803 | -913 | -1,074 | -925 | Upgrade
|
| Free Cash Flow Per Share | -18.05 | -18.47 | -26.25 | -42.34 | -43.31 | Upgrade
|
| Gross Margin | 98.44% | 100.00% | 89.66% | 94.92% | 75.00% | Upgrade
|
| Operating Margin | -735.94% | -308.56% | -3220.69% | -1866.10% | -13262.50% | Upgrade
|
| Profit Margin | -732.03% | -313.62% | -3213.79% | -1883.05% | -13237.50% | Upgrade
|
| Free Cash Flow Margin | -757.81% | -312.45% | -3148.28% | -1820.34% | -11562.50% | Upgrade
|
| EBITDA | -929 | -755 | -889 | -1,055 | -1,001 | Upgrade
|
| EBITDA Margin | - | -293.77% | - | - | - | Upgrade
|
| D&A For EBITDA | 13 | 38 | 45 | 46 | 60 | Upgrade
|
| EBIT | -942 | -793 | -934 | -1,101 | -1,061 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.